Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Quest Diagnostics (DGX)

Quest Diagnostics raises 2026 revenue and EPS guidance after 10% Q3 revenue growth

Positive Impact 4 of 5 guidance

Quest Diagnostics reported third-quarter 2026 net revenues of $3.10 billion, up 10.0% from a year earlier, with reported diluted EPS of $2.78, up 28.7%, and adjusted diluted EPS of $3.00, up 15.4%. The company raised its full-year 2026 revenue and EPS guidance, which matters to shareholders because the outlook for both revenue and earnings per share moved higher.

Key points

  • Q3 2026 net revenues of $3,097 million, up 10.0% from $2,816 million in Q3 2025
  • Q3 2026 reported diluted EPS of $2.78 vs. $2.16 a year earlier; adjusted diluted EPS of $3.00 vs. $2.60
  • Full-year 2026 reported diluted EPS now expected at $10.21 to $10.31, up from $9.97 to $10.17
  • Full-year 2026 net revenues now expected at $12.065 billion to $12.105 billion, up from $11.95 billion to $12.05 billion; the company will hold its 2027 Investor Day on March 25, 2027

The filing

CompanyQuest Diagnostics (DGX)
Form8-K, current report
Filed with the SECOct 22, 2026, 6:49 AM ET
Accession number0001022079-26-000097

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 7, 2026, 11:17 PM ET, from this filing only.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.